Advertisement

Journal of Thrombosis and Thrombolysis

, Volume 48, Issue 3, pp 359–365 | Cite as

Effects of body mass index on the safety and effectiveness of direct oral anticoagulants: a retrospective review

  • Jared NetleyEmail author
  • Kris Howard
  • William Wilson
Article
  • 539 Downloads

Abstract

Background

The International Society on Thrombosis and Haemostasis recommends avoiding the use of direct oral anticoagulants (DOACs) in patients with a body mass index (BMI) greater than 40 kg/m2 or weight greater than 120 kg.

Hypothesis

Higher BMI is associated with altered pharmacokinetics which may affect the safety and effectiveness for DOACs.

Methods

Data were collected on 3458 patients taking a DOAC prior to admission to a Midwestern health system between February 2013 and August 2016. Of these, 43 patients had a thrombotic event and 70 patients had an overt bleeding event. Patients were stratified among the following three BMI groups: BMI < 30 kg/m2, BMI 30–40 kg/m2, and BMI > 40 kg/m2.

Results

There was no statistically significant difference between BMI groups for thrombotic events (p = 0.598) or for overt bleeding events (p = 0.065). The BMI < 30 kg/m2 had the highest occurrence rate of bleeding events. It was observed that bleeding occurrence decreased as the BMI groups increased. The BMI > 40 kg/m2 group had the lowest risk of bleeding events, and was the only group to have a higher occurrence rate of thrombotic events compared to bleeding events.

Conclusions

Among patients admitted to a single health system on DOAC therapy over a three-and-a-half-year period, obesity did not significantly correlate with thrombotic or overt bleeding complications. This study is limited as a single health system study with low overall event rates. A preliminary finding of this study showed a trend towards decreased bleeding frequency as BMI increased.

Keywords

Direct oral anticoagulants Pharmacology Body mass index Obesity 

Notes

Acknowledgements

Sarah Meeks for mentorship & Sarah Ferrell and Christopher Liston for aiding in data collection.

Funding

Dr. William Wilson is a member on the Eliquis® Advisory Board but accepts no financial contributions. No financial support or grants were used to fund this study. All funding was done by Parkview Health.

References

  1. 1.
    Kearon C, Akl EA, Ornelas J et al (2016) Antithrombotic therapy for VTE disease: chest guideline and expert panel report. Chest 149(2):315–352CrossRefGoogle Scholar
  2. 2.
    January CT, Wann LS, Alpert JS et al (2014) 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 130(23):2071–2104CrossRefGoogle Scholar
  3. 3.
    Hirschl M, Kundi M (2014) New oral anticoagulants in the treatment of acute venous thromboembolism - a systematic review with indirect comparisons. VASA. 43(5):353–364CrossRefGoogle Scholar
  4. 4.
    Larsen TB, Skjøth F, Nielsen PB, Kjældgaard JN, Lip GY (2016) Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ 353:i3189CrossRefGoogle Scholar
  5. 5.
    Hellenbart EL, Faulkenberg KD, Finks SW (2017) Evaluation of bleeding in patients receiving direct oral anticoagulants. Vasc Health Risk Manag. 13:325–342CrossRefGoogle Scholar
  6. 6.
    Hanley MJ, Abernethy DR, Greenblatt DJ (2010) Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 49(2):71–87CrossRefGoogle Scholar
  7. 7.
    Martin K, Beyer-Westendorf J, Davidson BL, Huisman MV, Sandset PM, Moll S (2016) Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. J Thromb Haemost 14(6):1308–1313CrossRefGoogle Scholar
  8. 8.
    Dobesh PP, Fanikos J (2016) Reducing the risk of stroke in patients with nonvalvular atrial fibrillation with direct oral anticoagulants. Is one of these not like the others? J Atr Fibrillation 9(2):1481Google Scholar
  9. 9.
    Cohen AT, Imfeld S, Rider T (2014) Phase III trials of new oral anticoagulants in the acute treatment and secondary prevention of VTE: comparison and critique of study methodology and results. Adv Ther. 31(5):473–493CrossRefGoogle Scholar
  10. 10.
    Noseworthy PA, Yao X, Abraham NS, Sangaralingham LR, Mcbane RD, Shah ND (2016) Direct comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in nonvalvular atrial fibrillation. Chest 150(6):1302–1312CrossRefGoogle Scholar
  11. 11.
    Tittl L, Endig S, Marten S, Reitter A, Beyer-westendorf I, Beyer-westendorf J (2018) Impact of BMI on clinical outcomes of NOAC therapy in daily care—results of the prospective Dresden NOAC Registry (NCT01588119). Int J Cardiol 262:85–91CrossRefGoogle Scholar
  12. 12.
    Kaatz S, Ahmad D, Spyropoulos AC, Schulman S (2015) Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost 13:2119–2126CrossRefGoogle Scholar
  13. 13.
    Cunningham A, Stein CM, Chung CP, Daugherty JR, Smalley WE, Ray WA (2011) An automated database case definition for serious bleeding related to oral anticoagulant use. Pharmacoepidemiol Drug Saf 20(6):560–566CrossRefGoogle Scholar
  14. 14.
    Barbar S, Noventa F, Rossetto V et al (2010) A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost 8(11):2450–2457CrossRefGoogle Scholar
  15. 15.
    Ruíz-giménez N, Suárez C, González R et al (2008) Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 100(1):26–31CrossRefGoogle Scholar
  16. 16.
  17. 17.
    Graves KK, Edholm K, Johnson SA (2017) Use of oral anticoagulants in obese patients. JSM Atheroscler. 2(4):1035Google Scholar
  18. 18.
    Tittl L, Endig S, Marten S, Reitter A, Beyer-westendorf I, Beyer-westendorf J (2018) Impact of BMI on clinical outcomes of NOAC therapy in daily care - Results of the prospective Dresden NOAC Registry (NCT01588119). Int J Cardiol 262:85–91CrossRefGoogle Scholar
  19. 19.
    Lavie CJ, Mcauley PA, Church TS, Milani RV, Blair SN (2014) Obesity and cardiovascular diseases: implications regarding fitness, fatness, and severity in the obesity paradox. J Am Coll Cardiol 63(14):1345–1354CrossRefGoogle Scholar
  20. 20.
    Hainer V, Aldhoon-hainerová I (2013) Obesity paradox does exist. Diabetes Care 36(Suppl 2):S276–S281CrossRefGoogle Scholar
  21. 21.
    Hansel B, Roussel R, Elbez Y et al (2015) Cardiovascular risk in relation to body mass index and use of evidence-based preventive medications in patients with or at risk of atherothrombosis. Eur Heart J 36(40):2716–2728CrossRefGoogle Scholar
  22. 22.
    Abed HS, Wittert GA (2013) Obesity and atrial fibrillation. Obes Rev 14(11):929–938CrossRefGoogle Scholar
  23. 23.
    Stein PD, Beemath A, Olson RE (2005) Obesity as a risk factor in venous thromboembolism. Am J Med 118(9):978–980CrossRefGoogle Scholar
  24. 24.
    Sandhu RK, Ezekowitz J, Andersson U et al (2016) The ‘obesity paradox’ in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial. Eur Heart J 37(38):2869–2878CrossRefGoogle Scholar
  25. 25.
    Balla SR, Cyr DD, Lokhnygina Y et al (2017) Relation of risk of stroke in patients with atrial fibrillation to body mass index (from patients treated with rivaroxaban and warfarin in the rivaroxaban once daily oral direct factor xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation trial). Am J Cardiol 119(12):1989–1996CrossRefGoogle Scholar
  26. 26.
    Schulman S, Kearon C, Kakkar AK et al (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361(24):2342–2352CrossRefGoogle Scholar
  27. 27.
    Büller HR, Décousus H, Grosso MA et al (2013) Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 369(15):1406–1415CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of PharmacyParkview HealthFort WayneUSA
  2. 2.Department of CardiologyParkview HealthFort WayneUSA

Personalised recommendations